Aclaris Therapeutics, Inc. (ACRS)

Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	-	24.57	39.88	45.28	27.35	22.06
Short-Term Investments	-	89.02	79.23	172.29	164.07	32.07
Cash & Short-Term Investments	105.31	113.59	119.11	217.57	191.41	54.13
Cash Growth	-5.20%	-4.63%	-45.26%	13.66%	253.61%	-26.12%
Receivables	-	8.92	0.3	0.48	0.62	0.77
Prepaid Expenses	-	3.44	9.45	13.5	13	2.59
Total Current Assets	-	125.95	128.86	231.55	205.03	57.49
Property, Plant & Equipment	-	3.85	5.48	3.78	4.77	5.78
Long-Term Investments	-	90.3	62.77	12.24	34.24	-
Other Intangible Assets	-	-	-	6.97	7.05	7.12
Other Long-Term Assets	-	0.22	0.3	0.05	0.12	0.39
Total Assets	-	220.33	197.41	254.6	251.21	70.78
Accounts Payable	-	4.69	8.88	10.35	9.99	5.25
Accrued Expenses	-	7.6	10.86	8.2	7.37	5.91
Current Portion of Leases	-	0.48	0.43	0.68	0.72	0.6
Current Unearned Revenue	-	3.89	-	-	-	-
Other Current Liabilities	-	14.94	10.79	2.7	4.85	3.11
Total Current Liabilities	-	31.6	30.95	21.94	22.93	14.87
Long-Term Debt	-	-	-	-	-	10.65
Long-Term Leases	-	2.12	3.07	1.57	2.17	2.89
Long-Term Unearned Revenue	-	20.04	-	-	-	-
Long-Term Deferred Tax Liabilities	-	-	-	0.37	0.37	0.37
Other Long-Term Liabilities	-	11.02	6.2	33.1	28.4	4.35
Total Liabilities	-	64.77	40.23	56.98	53.87	33.13
Common Stock	-	0	0	0	0	-
Additional Paid-In Capital	-	1,058	928.08	880.83	792.97	542.29
Retained Earnings	-	-902.86	-770.8	-682.32	-595.41	-504.54
Comprehensive Income & Other	-	0.1	-0.11	-0.9	-0.22	-0.09
Total Common Equity	144.07	155.55	157.18	197.62	197.34	37.65
Shareholders' Equity	144.07	155.55	157.18	197.62	197.34	37.65
Total Liabilities & Equity	-	220.33	197.41	254.6	251.21	70.78
Total Debt	2.48	2.6	3.5	2.25	2.89	14.15
Net Cash (Debt)	188.04	201.3	178.38	227.56	222.76	39.98
Net Cash Growth	27.87%	12.85%	-21.61%	2.15%	457.17%	-42.11%
Net Cash Per Share	1.83	2.60	2.56	3.49	3.93	0.94
Filing Date Shares Outstanding	122.58	107.92	70.93	66.69	61.28	51.8
Total Common Shares Outstanding	122.58	107.85	70.89	66.69	61.23	45.11
Working Capital	-	94.36	97.9	209.61	182.1	42.62
Book Value Per Share	1.33	1.44	2.22	2.96	3.22	0.83
Tangible Book Value	144.07	155.55	157.18	190.65	190.29	30.53
Tangible Book Value Per Share	1.33	1.44	2.22	2.86	3.11	0.68
Machinery	-	5	4.97	4.01	3.61	3.15
Leasehold Improvements	-	0.82	0.82	1.12	1.12	1.12

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q